News Headline Summary

Eli Lilly (LLY) reaffirms forecast for 2012

- Sees Q4 charge in the range of USD 20-35mln pretax
- Sees about USD 0.02 charge.

- Elsewhere, the company has stopped one of three phase 3 Rheumatoid Arthritis registration, cites did not meet efficacy views.

13 Dec 2012 - 14:01 - Equities - Source: Newswires

Subscribe Now to RANsquawk

Click here for a 1 week free trial

RANsquawk provides audio news and commentary for over 15,000 professional traders and brokers worldwide. Services include: